<DOC>
	<DOC>NCT00261313</DOC>
	<brief_summary>This is a study of dose dense doxorubicin/cyclophosphamide (AC) followed by paclitaxel (Taxol; T) with pegfilgrastim (Neulasta) and darbepoetin alfa support in the adjuvant breast cancer setting.</brief_summary>
	<brief_title>ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Breast cancer diagnosis nodepositive or high risk node negative Estrogen receptor (ER) negative or ER positive (stage IIA, IIB or IIIA) disease. Metastatic breast cancer Clinically significant cardiac disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Doses dense chemotherapy</keyword>
	<keyword>Growth factor support</keyword>
	<keyword>Adjuvant Breast Cancer</keyword>
</DOC>